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Bactericidal effects of levofloxacin in comparison 
with those of ciprofloxacin and sparfloxacin 
Inga Odenhol t ,  Elisabeth Lowdin and O t t o  Cars 
Antibiotic Research Unit, Department of Infectious Diseases and Clinical Microbiology, 
University Hospital, Uppsala, Sweden 
Objective: To investigate and compare the in vitro activity of levofloxacin with the activities of ciprofloxacin and 
sparfloxacin. 
Methods: The following experiments were performed: (1) comparative studies of the rate of killing by the three 
quinolones of different strains of Streptococcus pneurnoniae at a concentration corresponding to the I - h  serum level 
following a 500-mg dose in humans; (2) comparative studies of the rate of killing by levofloxacin and ciprofloxacin of 
different strains of Sraphylococcus aureus, Escherichia coli and fseudomonas aeruginosa at the same concentrations 
as above; (3) comparative studies of the rate of killing by levofloxacin at four different concentrations of reference and 
clinical strains of Streptococcus pneumoniae, Staphylococcus aureus, E. coli and I? aeruginosa. 
Results: Levofloxacin exhibited statistically significantly higher bactericidal activity than sparfloxacin after 2 and/or 
3 h against all strains of Streptococcus pneurnoniae. Compared to ciprofloxacin, levofloxacin showed a statistically 
significantly higher bactericidal activity after 2 and/or 3 h against all strains of Streptococcus pneurnoniae except the 
one resistant to both penicillin and cefotaxime. No differences in killing rate between levofloxacin and ciprofloxacin were 
seen against Staphylococcusaureus, E. coliand I? aeruginosa, with almost complete killing after 3 h of the i? aeruginosa 
strains and after 6 h for the E. colistrains. N o  concentration-dependent killing was seen at concentrations above 4xMIC 
of levofloxacin against Staphyloccus aureus, E. coli and I? aeruginosa. 
Conclusion: Levofloxacin was shown t o  be active against both Gram-positive and Gram-negative bacteria. In terms of 
MIC values, ciprofloxacin was the most active drug against the Gram-negative organisms, and sparfloxacin against the 
strains of Streptococcus pneumoniae, but levofloxacin exhibited a similar or even better bactericidal activity against the 
investigated strains compared with the other two fluoroquinolones when killing curves were compared. 
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INTRODUCTION 
During the last decade, the fluoroquinolone anti- 
niicrobial agents have been established as important 
therapeutic agents. They are characterized by a broad 
antibacterial spectrum and rapid bactericidal activity 
[ 1-51. Among the currently available agents, cipro- 
floxacin, ofloxacin and spaifloxacin have been approved 
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for the treatment of respiratory tract infections [I]. 
However, despite the widespread use of ciprofloxacin 
and ofloxacin, there have been concerns about their 
activity against Gram-positive bacteria [6] .  During the 
late 1980s and 199Os, several agents with better activity 
against Gram-positive bacteria have been developed. 
T h e  firvt of  these agents, temafloxacin, was withdrawn 
because of  unexpected serious adverse reactions [7,8]. 
Sparfloxacin has been licensed in several countries but, 
due to a relatively high incidence of phototoxicity, 
its indications have been restricted, e.g. in France. 
Ofloxacin is a racemic mixture of levofloxacin (L- 
ofloxacin) and D-ofloxacin. Levofloxacin has been 
shown to be the more active component, with 
antibacterial activity 8-128 times that of  D-ofloxacin, 
and this difference in activity correlates with differences 
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in the DNA gyrase inhibitory activities of the two 
compounds [9-131. Compared with ciprofloxacin, 
levofloxacin is also two to four times more active against 
Gram-positive bacteria but with higher minimum 
inhibitory concentrations (MJCs) against Pseudomonas 
aeruginosa. The aim of the present study was to 
investigate the bactericidal effects of levofloxacin in 
comparison to those of ciprofloxacin and sparfloxacin, 
and the following experiments were performed: (I)  
comparative stuhes of the rate of killing by the three 
quinolones of different strains of Streptococcus pneumoniae 
at a concentration corresponding to the 1-h serum level 
following a 500-mg dose in humans; (2) comparative 
studies of the rate of killing by levofloxacin and 
ciprofloxacin of different strains of Staphylococcus aureus, 
Escherichia coli and P aerugirzosu at the same concentra- 
tions as above; (3) comparative studies of the rate of 
k&ng by levofloxacin at four different concentrations 
of reference and clinical strains of Streptococcus pneu- 
nioniae, Staplzylococcus aureus, E. coli and l? aeruginosa. 
MATERIALS AND METHODS 
Antibiotics 
Levofloxacin was provided by Hoechst-Marion- 
Roussel (HMR), Romainville Cedex, France, spar- 
floxacin by RhBne-Poulenc Rorer, Helsingborg, 
Sweden, and ciprofloxacin by Bayer, Stockholm, 
Sweden. The antibiotics were obtained as reference 
powders with known potency. All substances were 
dissolved in 0.1 M sodium hydroxide saline and 
thereafter diluted in broth. The solutions were made on 
the same day as the experiments were performed. 
Bacterial strains and media 
The strains used in the study included Streptococcus 
przeurnoniae ATCC 6306 (penicillin sensitive; Pc S), 
and clinical isolates of Streptococcus pneumoniae 5043 
@enic&n intermediate; Pc I), 1020 (penicillin resistant; 
Pc R) and 32475 (penicdhn and cefotaxime resistant; 
CTX R). Five strains of Staphylococcus aureus, HBD 2, 
4, 10, 17 (methicillin resistant) and 456 (methicillin 
sensitive), obtained from HMR, Romainville, France 
were tested. The Gram-negative strains studied were E. 
coli ATCC 25922 and one clinical isolate ofE. coli 1058; 
and I? aeruginosa ATCC 27853 and one clinical isolate 
of the same species 519-5019 (ceftazidime resistant). 
The clinical strains were obtained from the Clinical 
Microbiological Laboratory, Uppsala, Sweden. The 
Gram-negative strains were grown in Mueller-Hinton 
(M-H) broth (Difco Laboratories, Detroit, MI, USA), 
supplemented with 50 mg/L Ca2+ and 25 mg/L Mg+,  
for 6 h at 37"C, yielding an initial inoculum of 
approximately 5 x 10' CFU/mL. Staphylococcus aureus 
and Streptococcus pneumoniae were grown in Todd- 
Hewin: broth (T-H), for 6 h at 37"C, resulting in 
approximately lo9 C F U / d .  
Determination of minimum inhibitory concentrations 
(MICs) 
The MICs for the strains used in the experiments 
were determined by a macrodilution technique. Two- 
fold serial dilutions of the antibiotics, including also 
benzylpenicillin for the strains of Streptococcus pneu- 
moniae and oxacillin for the strains of Staphylococcus 
aureus, were made in M-H broth (Gram-negative 
strains) or in T-H broth (Gram-positive strains) and 
inoculated with a final inoculum of approximately 
lO'CFU/ml. of the test strains. The tubes were 
thereafter incubated at 37°C and read after 24 h. The 
MIC was defined as the lowest concentration of 
antibiotic allowing no visible growth. 
Determination of the rate of killing by levofloxacin, 
ciprofloxacin and sparfloxacin of Streptococcus 
pneumoniae at a concentration reached in human 
serum 1 h after 500 mg IV 
A concentration corresponding to the 1 -h serum level 
following a 500-mg dose in humans of the three anti- 
biotics [14-161 was used (5.5 mg/L for levofloxacin, 
2.5 mg/'L for ciprofloxacin and 1.5 mg/L for spar- 
floxacin). Tubes, containing medium with the addition 
of the antibiotic, were inoculated with a suspension 
of the test strain, giving a final bacterial count of 
approximately 5 x 10' CFU/mL and incubated at 
37°C. Samples were withdrawn at 0, 1, 2, 3, 6, 9 and 
12 h an'd diluted in phosphate-buffered saline. Three 
dilutions of each sample were spread on blood agar 
plates (Colombia agar base with 5% horse blood), 
incubated at 37°C and counted after 24 h. Only plates 
with 20-500 colonies were counted. All three anti- 
biotics were tested against Streptococcus pneumoniae 
ATCC 6306 (Pc S), and the clinical isolates of 
Streptococcus pneumoniae 5043 (Pc I), 1020 (Pc R) and 
32475 (CTX K). Three experiments were performed 
for each antibiotic-bacterial combination. 
Determination of the rate of killing by levofloxacin 
and ciprdoxacin of Staphylococcus aureus, E. coliand 
F! aemginosa 
Tubes, containing medium with the addition of the 
antibiotics at the same concentrations as above, were 
inoculated with a suspension of the test strains, 
giving a final bacterial count of approximately 
5 x 1 0' C : F U / d ,  and incubated at 37°C. The samples 
were diluted and counted as described above. Levo- 
floxacin and ciprofloxacin were studied against five 
strains of Staphylococclrs aureus, HBD 2, 4, 10, 17 and 
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456, E. coli ATCC 25922 and one clinical isolate of the 
same species 1058, and I? nenzinosu ATCC 27853 and 
one clinical isolate of the same species 5019. Three 
experiments were performed for each antibiotic- 
bacterial combination. 
Determination of the rate of killing by levofloxacin at 
different concentrations 
In this study, different concentrations of levofloxacin 
were used. Tubes, containing 4 ml of adequate medium 
with the addition of the antibiotic at 2, 4, 8, and 
16xMIC respectively, were inoculated with a suspen- 
sion of the test strain, giving a final bacterial count 
of approximately 5 x  10' CFU/mL. The tubes were 
incubated at 37°C and samples were then withdrawn 
and counted as described above. Levofloxacin was 
tested against Streptococcus prierrmoniae ATCC 6306 
(Pc S) and 1020 (Pc R), Sfuphylococcus auretis HBD 2 
(MRSA) and HBD 456 (MSSA), E. cidi ATCC 25922, 
and P aerqinosa ATCC 27853. The experiments were 
performed in triplicate. 
Statistics 
The Student's r-test for unpaired samples was used to 
compare the bactericidal activities of the different 
quinolones. 
RESULTS 
Minimum inhibitory concentrations 
The MIC values for the various strains are shown in 
Table 1. 
Rate of killing of Streptococcus pneumoniae at a 
concentration reached in human serum 1 h after 
500 mg IV 
Levofloxacin exhibited statistically significantly higher 
bactericidal activity than spadoxacin after 2 and/or 3 h 
against d strains of Streptococcus pneunioniae. Compared 
to ciprofloxacin, levofloxacin showed a statistically 
significantly higher bactericidal activity after 2 and/or 
3 h against all strains of Streptococcus prreumoriine except 
the one resistant to both penicillin and cefotaxime 
Table 1 The rn1niInal inhibitory concentrations of levo- 
floxacin, ciprofloxacin and spadoxacln for the investigated 
strains 
Benzy- 
prnicillin 
Streptocorcirs prierrniuniae 
ATCC 6306 1 .O 
238-5043 1 .I) 
5-1020 0.5 
32475 1 .o 
Stapiiylocuccirs a i i rwz  
HBl) 2 0.25 
HBI) 4 16 
HBII 10 0.5 
HBD 17 8.0 
HBII 456 0.2.5 
E. colr 
ATCC: 25922 0.03 
437-1058 0.03 
1" aenryiriosa 
ATCC 27853 2.0 
519-5Ol9 1.0 
1 .o 
l i .5 
11.5 
0.J 
0.25 
li.5 
I).i 
6-1 
16 
O.O(J8 
0.008 
1 .o 
i l  13 
f ) . 2 i  
0.125 
0.25 
0.25 
N1) 
ND 
ND 
NI 
NI) 
0.0 I6 
NI 1 
1.0 
1.0 
0.03 
0.25 
2.0 
4.0 
C)sacillin 
64 
1 
32 
32 
1).5 
(Table 2). Figure I shows the killing by the three 
quinolones of the penicillin-sensitive strain. 
Rate of killing of Staphylococcus aureus, F. co/i and 
F! aeruginosa at a concentration reached in human 
serum 1 h after 500 mg IV 
No differences in killing rate between levofloxacin 
and ciprofloxacin were seen against Stapliylococcrrr auretis 
HBD 2, 10 and 456, with a 3 to 4 logll, CFU killing 
after 6 h (Figure 2). No bactericidal activity was seen 
for any of the drugs against HBD 4 and HBD 17 at 
these concentrations (data not shown). No difference 
in killing was seen between levofloxacin and cipro- 
floxacin against E. coli or I! nerrgirrosa (Figure 3), with 
almost complete killing afier 1-3 h of the I! aemginosn 
strains and after 6 h of the E. coli strains. 
Rate of killing of levofloxacin at different concentrations 
No concentration-dependent killing was seen at  
concentrations above 4xMIC of levofloxacin of 
Table 2 Bactericidal activity 06 levofloxacin, ciprofloxacin and sparfloxacin against strains of Streptococctis pnertrnonine after 
different time paints (A loglo CFU) 
Streprococcus prieiinioniae Streplococcus priciinioniae 
Strain ATCC: 6306 ,043 
I h  2 h  3 h  6 h  l h  2 h  3 h  6 h  
Levofloxacin 1.8 3.8 4.8 >J.9 0.9 2.0 3.6 >4 . l  
Ciprofloxacin 1.1 1.7*** 2.4*** 3.7** 0.5 1.5 2.3** 3.9 
Sparfloxacin 0.5 1.7*** ?.A*** 3.7*+ 0.5 0.9* 1.9*** 3.9 
~ ~~~ ~ 
Strepfotoccir c pnewnr orirar Srrcpromcctts ptreiiwiorriae 
1020 32475 
I h  2 h  3 h  h h  1 h  2 h  3 h  6 h  
3.8 >4.6 N . 6  >4.6 0.8 1.5 2.0 3.2 
NU 1.9*** 3.1*** >4.6 0.4 0.8* 1.2 2.4 
1.7 3.3*** 4 2  24 .6  0.6 1.0 1.5 2.9 
'p<O 05. *'p%O 111. "*pSO 001 in cornpanson wth  the results for levofloxacin 
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Figure 1 Time-lulling curves of levofloxacin, ciprofloxacin and sparfloxacin against Streptocouus pneumoniae ATCC 6306 at a 
concentration reached in human serum 1 h after 500 mg IV (mean CFU/mL 5 SD). Limit of detection 10 CFU/mL. 
1 
Figure 2 Time-lulling curves of levofloxacin and ciprofloxacin against St~rrpl~ylococcus airreus HBD 2 and 10 at a concentration 
reached in human serum 1 h after 500 mg IV (mean CFU/mL 2 SD). Limit of detection 10 CFU/mL. 
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F4 " ,-=- Levotloxacin/E. coli 
--+-- Ciprofloxacin/E. coli 
----o--- Control/E. coli 
----&---- Levofloxacin/l? aeruginosa 
+ Ciprotloxacin/l? aemginosa 
- . Q - Control/l? aeruginosa 
0 I ! I I 1 
0 2 4 6 8 10 h 
Figure 3 Time-killing curves of levofloxacin and ciprofloxacin against F! aenqinora ATCC 27 853 and E. c d i  ATCC 25 Y22 
at  a concentration reached in human serum 1 h after 500 mg IV (mean CFU/mL k SD). Limit of detection 10 CFU/mL. 
Table 3 Kdling by levofloxacin at different concentrations 
afier 3 h (A loglo CFU) 
DISCUSSION 
Levofloxacin is one of the new fluoroquinolones 
with increased activity against Gram-positive strains 
[2,3,12,13]. Pharmacologic studies have demonstrated 
that the pharmacohnetic characteristics of ofloxacin 
2XMIC 4XMIC 8XMIC 16xMIC 
Srreptococm prirumoiiiar 
ATCC 6306 2.9 3.9 4.1 4.4 
Streptocuiciis pnruniori~~~le 
1070 3.0 4.0 >4.8 >4.8 
Stdphylomcciii aurciic 
HBD li i  1.8 2.2 2.2 7 7  
Staphyloiorciis uiireiis 
HHI) 456 7 3  3.0 3.0 3.0 
E .  roli 
ATCC 25922 1 . 2  4.4 4.0 3.8 
I' arniLyiirora 
ATCC 27853 >4.x >4.8 >4.8 >4 .8  
are shared by the L-isomer when this is given alone. 
A C,,, of 3.5 mg/L has been measured for levo- 
floxacin, compared with 2.5 mg/L for ciprofloxacin 
and 1.5 mg/L for spadoxacin [14-16]. With its long 
half-life of 7-8 h, clinical studies with 500 mg given 
once daily have demonstrated success. The most often 
used parameter to describe antibacterial activity is 
still the minimum inhibitory concentration (MIC). 
However, other pharmacodynamic properties, such ac 
the rate and extent of killing, whether the lulling is 
concentration-dependent or not and the postantibiotic 
effects, have been recognized as important factors 
that may influence the optimal dosing regimens for 
antibiotics 117-221. 
In the present study, the MICs of levofloxacin for 
the Gram-positive strains were very similar to those of 
ciprofloxacin. The lowest MIC values for Streptococcus 
Pnetrmonifle were Seen with SParffoxacin, which is in 
accordance with the results of other authors [23] .  
Against Staphylococcus aureus, both levofl oxacin and 
Staphylucuccur a i i re tq  E. coli and I? aeruginosa (Table 3). 
A tendency towards a paradoxical effect was noted for 
the E. co/i strain, with slower lulling at high concen- 
trations compared to that at  lower concentrations 
(Table 3) .  Against two strains of Streptococcus pneumoniae, 
maximal killing was Seen at 8 and 1 6 ~ ~ 1 ~  respec- 
tively. 
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ciprofloxacin were active against the methicillin- 
sensitive strain and against two of four methicillin- 
resistant strains. Several other investigations have 
reported higher MIC values of levofloxacin compared 
to those of ciprofloxacin for Gram-negative strains 
[2,3,13]. This is in accordance with the findings in 
this study. However, levofloxacin was as active as 
ciprofloxacin when killing curves were compared. No 
difference in kihng was noted against E. coli ATCC 25 
922, with 99.99% killing after 6 h. Against the clinical 
E. coli strain, complete killing was noted after only 
3 h. Both drugs killed l? aeruginosa ATCC 27 853 
completely after 1 h and the clinical strain after 3 h. 
This is in accordance with the findings of Morissey and 
Smith [ l l ] .  They showed that even if ciprofloxacin 
had lower MIC values for different strains of Pseudo- 
monas, levofloxacin had more than 10 times greater 
bactericidal activity, measured with time-killing curves, 
than ciprofloxacin. The same tendency was found in 
the present study against Streptococcus pneumoniae. 
Levofloxacin exhibited statistically significantly higher 
bactericidal activity after 2 h against all strains of 
Streptococcus pneumoniae, and also after 3 h against all 
but one strain, than sparfloxacin. Compared to cipro- 
floxacin, levofloxacin showed statistically significantly 
higher bactericidal activity after 2 h against two of 
the four investigated Streptococcus pneumoniae strains. 
For almost all investigated strains, maximal k i h g  was 
reached at 4-8xMIC. 
In conclusion, the present study has shown that 
levofloxacin is active against both Gram-positive and 
Gram-negative bacteria. Even if ciprofloxacin was more 
active against the Gram-negative bacteria and spar- 
floxacin against Streptococcus pneumoniae in terms of 
MIC values, levofloxacin exhibited similar or even 
better bactericidal activity than the other two fluoro- 
quinolones when time-killing curves were compared. 
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